Michael King
Stock Analyst at EF Hutton
(0.79)
# 3,987
Out of 5,055 analysts
116
Total ratings
34.43%
Success rate
-15.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $24.54 | +2,548.74% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $5.92 | +19,818.92% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $3.38 | +225.44% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.28 | +2,400.00% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $1.68 | +3,977.38% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $14.79 | +1,252.27% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.92 | +803.94% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $693.50 | +24.30% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $41.65 | -42.38% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $4.33 | +3,733.72% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $14.93 | +181.31% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $449.16 | -32.32% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $8.70 | +1,233.33% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.83 | +113.25% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $37.41 | -35.85% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15,000 → $12,000 | $1.20 | +999,900.00% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $33.82 | +36.01% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $43.65 | +119.93% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.71 | +4,990.50% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $33.54 | -7.57% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $907.98 | -96.04% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $24.54
Upside: +2,548.74%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $5.92
Upside: +19,818.92%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $3.38
Upside: +225.44%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.28
Upside: +2,400.00%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $1.68
Upside: +3,977.38%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $14.79
Upside: +1,252.27%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.92
Upside: +803.94%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $693.50
Upside: +24.30%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $41.65
Upside: -42.38%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.33
Upside: +3,733.72%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $14.93
Upside: +181.31%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $449.16
Upside: -32.32%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $8.70
Upside: +1,233.33%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $4.83
Upside: +113.25%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $37.41
Upside: -35.85%
Mar 11, 2022
Maintains: Buy
Price Target: $15,000 → $12,000
Current: $1.20
Upside: +999,900.00%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $33.82
Upside: +36.01%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $43.65
Upside: +119.93%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.71
Upside: +4,990.50%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $33.54
Upside: -7.57%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $907.98
Upside: -96.04%